Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development [Accessibility Statement] Skip Navigation- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies.- In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for 7 days. ASC36 tablets also reduced food intake significantly.- In a head-to ...

Article 14, paragraph 1 of the law of 2 May 2007 on disclosure of major shareholdings Ascencio has received a transparency declaration from Carl, Eric and John Mestdagh as well as the controlled companies informing her that they now jointly hold 787,418 voting rights in the Company. They jointly declare a 11.94% shareholding. Crossing of the 5% threshold upwards by Carl Mestdagh and CMHC SRL. Attachment 2026 05 02 - Mestdagh - Transparency - UK ...

SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a press release on January 29th reporting positive topline results in the open-label Phase 3 trial evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne. Denifanstat is a once-daily oral sm ...

The Ordinary General Meeting of Shareholders of 30 January 2026 approved all the proposed resolutions on the agenda, which mainly concerned the financial statements of Ascencio SA for the year ended 30 September 2025. 1.779.647 shares of Ascencio SA were represented, or 27 % of the total number of shares in existence. Approval of the annual accounts of Ascencio SA and appropriation of profit The Meeting approved the distribution of a gross dividend of EUR 4.45 per share. The Meeting gave discharge, by separ ...

The Company will present an overview of its strategy and capital allocation framework, along with an in-depth update on key developments and the outlook for the product and chemical tanker market. The February 12, 2026 event will also include the Company's presentation of 4Q 2025 financial results. HAMILTON, Bermuda, Jan. 29, 2026 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore" or the "Company") today announced that it will host its 2026 Investor Day on Thursday, February 12 at 12:00 P. ...

Core Viewpoint - Ascletis Pharma Inc. announced positive topline results from a Phase III open-label study of denifanstat (ASC40), a first-in-class oral fatty acid synthase (FASN) inhibitor for treating moderate-to-severe acne vulgaris, indicating a potential breakthrough in acne treatment [1] Group 1: Study Results - Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile in a Phase III open-label study involving 240 patients, with most treatment-emergent adverse events (TEAEs) being mild (grade 1) or moderate (grade 2) [1] - No grade 3 or 4 adverse events or serious adverse events (SAEs) related to denifanstat (ASC40) were reported, and no deaths occurred during the study [1] Group 2: Mechanism of Action - The mechanism of action for denifanstat (ASC40) includes direct inhibition of sebum production by inhibiting de novo lipogenesis (DNL) in human sebocytes and reducing inflammation by decreasing cytokine secretion and Th17 differentiation [1] - This unique mechanism sets denifanstat (ASC40) apart from most other acne treatments, which do not address the underlying cause of acne [1] Group 3: Regulatory Progress - The New Drug Application for denifanstat (ASC40) for acne has been accepted by the China National Medical Products Administration, indicating progress towards commercialization [1] Group 4: Company Overview - Ascletis Pharma Inc. is a fully integrated biotechnology company focused on developing and commercializing potential best-in-class and first-in-class therapeutics for metabolic diseases [1] - The company utilizes proprietary technologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) to develop multiple drug candidates, including small molecules and peptides [1]

Core Insights - Ascletis Pharma Inc. is advancing its investigational drug ASC30, a GLP-1 receptor agonist, into a Phase II study for type 2 diabetes, with topline data expected in Q3 2026 [2][5] Group 1: ASC30 Development - ASC30 has shown a placebo-adjusted weight loss of up to 7.7% in a completed 13-week Phase II study for obesity, demonstrating better gastrointestinal tolerability compared to other treatments [1][3] - The Phase II study for diabetes will evaluate ASC30's efficacy, safety, and tolerability, focusing on changes in HbA1c and body weight among approximately 100 participants [5][6] - ASC30 is designed for once-daily oral administration and has been developed in-house by Ascletis as a first and only investigational small molecule GLP-1R fully biased agonist [4][6] Group 2: Clinical Study Details - The obesity Phase II study involved 125 participants and reported a treatment discontinuation rate due to adverse events of 4.8% [3] - The study for diabetes is randomized, double-blind, and placebo-controlled, with participants assigned to different dosages of ASC30 [5] - The primary endpoint of the diabetes study is the mean change in HbA1c from baseline, with secondary endpoints including fasting blood glucose and body weight changes [5]

Core Viewpoint - Ardmore Shipping Corporation (ASC) is given a buy rating due to a strong outlook for the product tanker market and favorable trading conditions for the company [1]. Group 1: Company Analysis - The company is currently trading at attractive levels, which enhances its investment appeal [1]. - The product tanker market is expected to perform well, contributing positively to ASC's financial prospects [1]. Group 2: Market Outlook - The overall outlook for the product tanker market is strong, indicating potential growth and profitability for companies operating in this sector [1].

Core Viewpoint - Ardmore Shipping Corporation (ASC) is given a buy rating due to a strong outlook for the product tanker market and favorable trading conditions for the company [1]. Group 1: Company Analysis - The company is positioned well in the product tanker market, which is expected to perform strongly [1]. - Ardmore Shipping Corporation is currently trading at attractive levels, enhancing its investment appeal [1]. Group 2: Market Outlook - The product tanker market is anticipated to experience growth, contributing positively to the company's performance [1].

Core Viewpoint - Ascencio has announced the acquisition of the Horizon Provence retail park in Monteux, France, for €22.8 million excluding VAT, aligning with its strategic focus on retail assets in attractive locations [1][6]. Group 1: Acquisition Details - The retail park covers an area of over 12,000 m² and consists of around twenty retail units, primarily featuring food retailers, which aligns with Ascencio's strategy [2][6]. - The acquisition is financed entirely through borrowings using available secured credit lines, and it is in line with the market value determined by an independent valuer [5]. Group 2: Location and Accessibility - The retail park is situated in a rapidly growing residential and tourist area in the Provence-Alpes-Côte d'Azur region, benefiting from high visibility and accessibility along the main road connecting Avignon to Carpentras [3]. - Its proximity to leisure parks and hotel complexes enhances its attractiveness as a retail complex [3]. Group 3: Sustainability Features - The asset is located near soft mobility hubs and has received BREEAM certification, indicating its sustainability credentials [4]. - It is equipped with 8 charging stations, nearly 1,500 m of photovoltaic panels, and around 1,000 m of shading systems [4]. Group 4: Financial Impact - The acquisition is expected to have an immediate positive annual impact of €0.07 on Ascencio's EPRA Earnings per share and will result in an increase of approximately 1.7% in its EPRA LTV ratio [5]. Group 5: Strategic Alignment - The transaction aligns with Ascencio's strategy of focusing on retail assets in suburban areas with a strong commercial mix centered around food retailers [6]. - The integration of Horizon Provence exemplifies Ascencio's selective and disciplined growth strategy aimed at creating long-term value [6].